BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Thermo Fisher wins contracts as pharma shifts production to US, CEO says - 2Every year, she thanks the trooper for the arrest that led to her sobriety
- 3Telescope in Chile captures stunning new picture of a cosmic butterfly
- 4Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
- 5The Excursion to Monetary Proficiency: Individual budget Triumphs
- Joshua Made Last-Second Seat Change That Saved His Life
- Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- 'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- Top 10 Moving Style Architects of the Year
- 'Fertiliser costs mean I'm better off not planting'
- 5 Most Expected Film Delivery
- SF Chinatown's historic Empress of China building being revived into cultural campus
- The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
